National Asset Management, Inc. Tg Therapeutics, Inc. Transaction History

National Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$32.5 - $48.96 $230,262 - $346,881	-7,085 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$41.61 - $54.3 $30,042 - $39,204	-722 Reduced 9.25%	7,085 $342,000
Q4 2020 Feb 04, 2021	SELL	$25.27 - $54.9 $163,320 - $354,818	-6,463 Reduced 45.29%	7,807 $407,000
Q3 2020 Nov 09, 2020	BUY	$18.49 - $27.24 $36,055 - $53,118	1,950 Added 15.83%	14,270 $382,000
Q2 2020 Jul 31, 2020	SELL	$8.9 - $21.84 $6,230 - $15,288	-700 Reduced 5.38%	12,320 $240,000
Q1 2020 May 06, 2020	BUY	$7.14 - $15.99 $18,706 - $41,893	2,620 Added 25.19%	13,020 $129,000
Q4 2019 Feb 10, 2020	BUY	$5.1 - $11.2 $509 - $1,120	100 Added 0.97%	10,400 $115,000
Q3 2019 Nov 12, 2019	SELL	$5.38 - $8.99 $538 - $899	-100 Reduced 0.96%	10,300 $58,000
Q2 2019 Aug 05, 2019	SELL	$6.27 - $8.65 $21,945 - $30,275	-3,500 Reduced 25.18%	10,400 $90,000
Q4 2018 Feb 08, 2019	BUY	$3.44 - $5.76 $47,816 - $80,064	13,900 New	13,900 $58,000

338

87.7M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.37B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.